Glycemic efficacy

Glycemic efficacy refers to the capacity of regulated glycemic levels to produce an effect in people with diabetes and heart disease.^[1] According to Zeev Vlodaver, Robert F. Wilson and Daniel J. Garry, "exenatide and liraglutide are synthetic GLP-1 agonists and have demonstrated glycemic efficacy (HbA1c reductions of between 0.7 and 2%) associated with mild weight loss."^[2] Glyburide, metformin and rosiglitazone have been assessed as a monotherapy in the durability of glycemic efficacy.^[3]

References

^ Marso, Steven P.; Stern, David M. (2004). Diabetes and Cardiovascular Disease: Integrating Science and Clinical Medicine. Lippincott Williams & Wilkins. p. 229. ISBN 978-0-7817-4053-1. Retrieved 29 April 2012.
^ Vlodaver, Zeev; Wilson, Robert F.; Garry, Daniel J. (31 January 2012). Coronary Heart Disease: Clinical, Pathological, Imaging, and Molecular Profiles. Springer. p. 475. ISBN 978-1-4614-1474-2. Retrieved 29 April 2012.
^ Holt, Richard I. G.; Cockram, Clive; Flyvbjerg, Allan; Goldstein, Barry J. (26 July 2011). Textbook of Diabetes. John Wiley & Sons. p. 861. ISBN 978-1-4443-4806-4. Retrieved 29 April 2012.

[Marso(M.D.)2004-1] Marso, Steven P.; Stern, David M. (2004). Diabetes and Cardiovascular Disease: Integrating Science and Clinical Medicine. Lippincott Williams & Wilkins. p. 229. ISBN 978-0-7817-4053-1. Retrieved 29 April 2012.

[VlodaverWilson2012-2] Vlodaver, Zeev; Wilson, Robert F.; Garry, Daniel J. (31 January 2012). Coronary Heart Disease: Clinical, Pathological, Imaging, and Molecular Profiles. Springer. p. 475. ISBN 978-1-4614-1474-2. Retrieved 29 April 2012.

[HoltCockram2011-3] Holt, Richard I. G.; Cockram, Clive; Flyvbjerg, Allan; Goldstein, Barry J. (26 July 2011). Textbook of Diabetes. John Wiley & Sons. p. 861. ISBN 978-1-4443-4806-4. Retrieved 29 April 2012.

[1]

[2]

[3]